{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03751735",
      "OrgStudyIdInfo": {
        "OrgStudyId": "WJEF.EDUJCTC"
      },
      "Organization": {
        "OrgFullName": "University of Jordan",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Efficacy of Wharton Jelly in Erectile Dysfunction",
      "OfficialTitle": "Evaluation of the Efficacy for Two Doses of Intracavernous Injection of Wharton Jelly Stem Cells for the Treatment of Diabetic Erectile Dysfunction"
    },
    "StatusModule": {
      "StatusVerifiedDate": "April 2019",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "January 27, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "January 13, 2019",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "February 26, 2019",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "November 13, 2018",
      "StudyFirstSubmitQCDate": "November 21, 2018",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "November 23, 2018",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "April 9, 2019",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "April 10, 2019",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor-Investigator",
        "ResponsiblePartyInvestigatorFullName": "Sophia Al-Adwan",
        "ResponsiblePartyInvestigatorTitle": "Researcher, Clinical coordinator",
        "ResponsiblePartyInvestigatorAffiliation": "University of Jordan"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Sophia Al-Adwan",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Efficacy of Intracavernous injection of Wharton jelly Mesenchymal stem cells for the treatment of erectile dysfunction in diabetic patients.",
      "DetailedDescription": "This study will be conducted at the Cell Therapy Center (CTC), Jordan, in which 22 male patients ranging from 25-70 years diagnosed with erectile dysfunction will be selected. This diagnosis is based on medical history, validated questionnaires, physical examinations, laboratory tests and specific diagnostic tests.\n\nThe patients are followed by clinical assessment, laboratory investigations as well as Doppler ultrasound.\n\nThe investigators hypothesize that the intracavernous injection of stem cells will facilitate the recovery of erectile function resulting in satisfying clinical outcomes in patients."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Erectile Dysfunction Associated With Type 2 Diabetes Mellitus"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Diabetes",
          "Wharton jelly mesenchymal stem cells",
          "efficacy"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "9",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Dose 1",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Wharton Jelly Mesenchymal stem cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Wharton Jelly Mesenchymal stem cells",
            "InterventionDescription": "Intracavernous injection of Wharton Jelly Mesenchymal stem cells.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Dose 1"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by Penile Doppler ultrasonography.",
            "PrimaryOutcomeDescription": "Patients will be evaluated for the efficacy of the intracavernous injection of Wharton Jelly derived Mesenchymal Stem Cells by Penile Doppler ultrasonography in which peak systolic velocity of the cavernosal arteries will be measured.",
            "PrimaryOutcomeTimeFrame": "12 months"
          },
          {
            "PrimaryOutcomeMeasure": "Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaires",
            "PrimaryOutcomeDescription": "The efficacy of the intracavernous injection of Wharton Jelly will be evaluated by scoring the SHIM/IIEF/EHS questionnaires.",
            "PrimaryOutcomeTimeFrame": "12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAdult male patients ranging from 25 to 70 years.\nHistory of chronic erectile dysfunction for at least six months.\nBaseline international index of erectile function (IIEF) score of < 26.\nNot interested or able to use phosphodiesterase type 5 inhibitor (PD5i) drug therapy and willing to forgo theses treatments for the first 6 month period following study treatment.\nBody Mass Index between 20-30.\nWilling to provide written informed consent, complete questionnaire, and to be available for all baseline treatment and follow up examinations required by protocol.\n\nExclusion Criteria:\n\nCurrent urinary tract or bladder infection.\nClinical/Laboratory evidence of transmissible diseases.\nClinically evident penile anatomical deformities(e.g., Peyronie's disease) or history of priapism.\nSkin irritation, infection, wound, sore or disruption in the immediate areas of skin entry for penile injection.\nCurrent or previous malignancy.\nUse of any non study treatment for erectile function within 4 weeks of study treatment.\nLack of willingness to continue through 6 months after study treatment.\nAny previous penile implant or penile vascular surgery.\nUncontrolled hypertension or hypotension(systolic blood pressure > 170 or < 90 mm Hg, and diastolic blood pressure > 100 or < 50 mm Hg).\nReported unstable cardiovascular disease (e.g., unstable angina, myocardial infarction within past 6 months, cardiac failure or life-threatening arrhythmia, congestive heart failure) or symptomatic postural hypotension within 6 months before screening.\nBleeding or clotting disorder, use of anticoagulant therapy.\nLab values for complete blood count (CBC), prothrombin time (PT)/ partial thromboplastin time (PTT)/ international normalized ratio (INR), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatinine falling outside the normal lab values.\nSystemic autoimmune disorder.\nSignificant active systemic or localized infection.\nReceiving immunosuppressant medications.\nPost-radical prostatectomy.",
      "HealthyVolunteers": "No",
      "Gender": "Male",
      "GenderBased": "Yes",
      "MinimumAge": "25 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Abdalla Awidi, MD",
            "OverallOfficialAffiliation": "Cell Therapy Center",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Cell Therapy Center",
            "LocationCity": "Amman",
            "LocationZip": "11942",
            "LocationCountry": "Jordan"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Undecided"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000007172",
            "ConditionMeshTerm": "Erectile Dysfunction"
          },
          {
            "ConditionMeshId": "D000003924",
            "ConditionMeshTerm": "Diabetes Mellitus, Type 2"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000003920",
            "ConditionAncestorTerm": "Diabetes Mellitus"
          },
          {
            "ConditionAncestorId": "D000044882",
            "ConditionAncestorTerm": "Glucose Metabolism Disorders"
          },
          {
            "ConditionAncestorId": "D000008659",
            "ConditionAncestorTerm": "Metabolic Diseases"
          },
          {
            "ConditionAncestorId": "D000004700",
            "ConditionAncestorTerm": "Endocrine System Diseases"
          },
          {
            "ConditionAncestorId": "D000012735",
            "ConditionAncestorTerm": "Sexual Dysfunction, Physiological"
          },
          {
            "ConditionAncestorId": "D000020018",
            "ConditionAncestorTerm": "Sexual Dysfunctions, Psychological"
          },
          {
            "ConditionAncestorId": "D000001523",
            "ConditionAncestorTerm": "Mental Disorders"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M6267",
            "ConditionBrowseLeafName": "Diabetes Mellitus",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6271",
            "ConditionBrowseLeafName": "Diabetes Mellitus, Type 2",
            "ConditionBrowseLeafAsFound": "Type 2 Diabetes Mellitus",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9369",
            "ConditionBrowseLeafName": "Erectile Dysfunction",
            "ConditionBrowseLeafAsFound": "Erectile Dysfunction",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10791",
            "ConditionBrowseLeafName": "Metabolic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M24556",
            "ConditionBrowseLeafName": "Glucose Metabolism Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7014",
            "ConditionBrowseLeafName": "Endocrine System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14698",
            "ConditionBrowseLeafName": "Sexual Dysfunction, Physiological",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21026",
            "ConditionBrowseLeafName": "Sexual Dysfunctions, Psychological",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3967",
            "ConditionBrowseLeafName": "Mental Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13625",
            "ConditionBrowseLeafName": "Psychotic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC19",
            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXM",
            "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
          }
        ]
      }
    }
  }
}